SAN DIEGO–(BUSINESS WIRE)–Imagenetix, Inc. (OTCBB: IAGX – News) today announced that its proprietary anti-inflammatory compound, 1-tetradecanol complex (1-TDC), intended for use in the treatment of periodontal disease and other widespread inflammatory conditions, has completed pre-IND assessment by the FDA Dental and Dermatology Division and received positive comments. The FDA response, issued after reviewing animal toxicity, [...]
{ Comments on this entry are closed }